Logo

Merck's Keytruda (pembrolizumab) Receives Expanded Label Approval for 1L nonsq. mNSCLC- with No EGFR and ALK Genomic Tumor

Share this

Merck's Keytruda (pembrolizumab) Receives Expanded Label Approval for 1L nonsq. mNSCLC- with No EGFR and ALK Genomic Tumor

Shots:

  • Approval is based on KEYNOTE-189- Ph III study where Keytruda combined with ALIMTA and Pt. CT showed improved results vs CT
  • KEYNOTE-189 (Keytruda +pemetrexed and Pt. CT vs CT alone): mPFS (8.8 vs 4.9mos); ORR (48% vs 19%); mDOR (11.2 vs 7.8mos); reducing death risk by half
  • Keytruda was first approved in 2017 in combination with pemetrexed and carboplatin by FDA for 1L nonsq. mNSCLC from Ph II (KEYNOTE-021)

Ref: Merck & Co. | Image:  Merck & Co.

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions